> REGN – As soon as the Lucentis and Avastin talks were over, most people left the room and didn't stick around for this talk.<
That’s not surprising because REGN is so darn late to the AMD game. You have to wonder what the heck they (and SNY) were thinking to not get going faster with their AMD program. VEGF-Trap has been around for a very long time.
On yesterday’s MS webcast, REGN CEO Len Schleifer revealed that the phase-2 AMD trial for VEGF-Trap will not have a Macugen arm because no one wants Macugen anymore.
Since Lucentis is not yet on the market, the phase-2 for VEGF-Trap will not have a control arm per se but will instead contain multiple arms of VEGF-Trap in various doses and dosing schedules.
Market Data 
Markets 
AI
